Gilead signs $3B licensing deal for Sangamo's gene-editing platform
Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments.
Thursday, February 22, 2018
Gilead signs $3B licensing deal for Sangamo's gene-editing platform
Gilead signs $3B licensing deal for Sangamo's gene-editing platform
Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments.
Related Posts:
Exxon CEO struggles to reverse Tillerson's legacy of failed bets- Finance minister says China can handle government debt risks
- For many factory towns, white collar job loss hurts the most
- Saudi women take the wheel, test-driving a new freedom
- Oprah Winfrey Sells Some Shares In Weight Watchers International
0 comments:
Post a Comment